Tuesday - November 26, 2024
FDA Issues 'Letter of Support' Encouraging Use of Synuclein-Based Biomarker, αSyn-SAA, in Clinical Trials in Parkinson's and Related Diseases
September 10, 2024
NEW YORK, Sept. 10 -- The Michael J. Fox Foundation for Parkinson's Research issued the following news release:

* * *

* U.S. regulatory agency recognizes potential of alpha-synuclein seed amplification assay (aSyn-SAA) to accelerate clear outcomes in drugmakers' trials following multi-stakeholder collaboration amongst The Michael J. Fox Foundation for Parkinson's Research and the Critical Path Institute

* Letter is latest milestone in the journey of the bio . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products